PHASE II STUDY OF PEMBROLIZUMAB PLUS SURVAXM FOR GLIOBLASTOMA AT FIRST RECURRENCE

被引：0
|
作者：
Ahluwalia, Manmeet [1 ]
Peereboom, David [1 ]
Rauf, Yasmeen [2 ]
Schilero, Cathy [1 ]
Ciolfi, Marci [1 ]
Ciesielski, Michael [3 ]
Fenstermaker, Robert [4 ]
机构：
[1] Cleveland Clin, Main Campus, Cleveland, OH 44106 USA
[2] Cleveland Clin, Dublin, OH USA
[3] Roswell Pk, Buffalo, NY USA
[4] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
来源：
NEURO-ONCOLOGY | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CTIM-10
引用
收藏
页码：34 / 35
页数：3
相关论文
共 50 条
  • [31] A Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Endometrial Carcinoma
    Makker, Vicky
    Rasco, Drew
    Dutcus, Corina
    Stepan, Daniel
    Li, Di
    Schmidt, Emmett
    Shumaker, Robert
    Young, Louise
    Taylor, Matthew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 152 - 153
  • [32] PHASE I/II TRIAL OF RADIATION THERAPY, TEMOZOLOMIDE AND PEMBROLIZUMAB FOLLOWED BY TEMOZOLOMIDE AND PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Dixit, Karan
    Kumthekar, Priya
    Kruser, Timothy
    Bloch, Orin
    Chandler, James
    Tate, Matthew
    Raizer, Jeffrey
    NEURO-ONCOLOGY, 2016, 18 : 19 - 19
  • [33] Phase Ib/II trial of lenvatinib plus pembrolizumab in urothelial cancer.
    Vogelzang, Nicholas J.
    Encarnacion, Carlos A.
    Cohn, Allen Lee
    DiSimone, Christopher
    Rasco, Drew W.
    Richards, Donald A.
    Taylor, Matthew H.
    Dutcus, Corina E.
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Guo, Matthew
    Schmidt, Emmett V.
    Mier, James Walter
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [34] Sorafenib plus Daily Low-dose Temozolomide for Relapsed Glioblastoma: A Phase II Study
    Zustovich, Fable
    Landi, Lorenza
    Lombardi, Giuseppe
    Porta, Camillo
    Galli, Luca
    Fontana, Andrea
    Amoroso, Domenico
    Galli, Costanza
    Andreuccetti, Michele
    Falcone, Alfredo
    Zagonel, Vittorina
    ANTICANCER RESEARCH, 2013, 33 (08) : 3487 - 3494
  • [35] Sorafenib plus daily low dose temozolomide for relapsed glioblastoma: A phase II study.
    Zustovich, F.
    Landi, L.
    Lombardi, G.
    Galli, L.
    Porta, C.
    Amoroso, D.
    Fontana, A.
    Andreuccetti, M.
    Galli, C.
    Falcone, A.
    Zagonel, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Imatinib plus hydroxyurea in pretreated nonprogressive glioblastoma (GBM) - A single center phase II study
    Dresemann, Gregor
    Hosius, Christian
    Nikolova, Zariana
    ANNALS OF ONCOLOGY, 2006, 17 : 263 - 263
  • [37] Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
    Taylor, Matthew H.
    Vogelzang, Nicholas J.
    Cohn, Allen Lee
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Dutcus, Corina E.
    Guo, Matthew
    Schmidt, Emmett V.
    Rasco, Drew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [38] A PHASE II STUDY OF THE PANITUMUMAB plus IRINOTECAN THERAPY FOR ADVANCED/RECURRENCE COLORECTAL CANCER (TOPIC STUDY)
    Denda, T.
    Nishi, T.
    Yamaguchi, K.
    Kenji, A.
    Miyata, Y.
    Yamanaka, Y.
    Yanai, K.
    Hamamoto, Y.
    Nagase, M.
    Fujii, H.
    ANNALS OF ONCOLOGY, 2013, 24
  • [39] Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma
    Harrington, K. J.
    William, W. N., Jr.
    Khilnani, A.
    Algazi, A. P.
    ANNALS OF ONCOLOGY, 2020, 31 : S683 - S683
  • [40] Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Bocobo, Andrea Grace
    Wang, Renee
    Behr, Spencer
    Carnevale, Julia C.
    Cinar, Pelin
    Collisson, Eric Andrew
    Fong, Lawrence
    Keenan, Bridget P.
    Kidder, Wesley Allen
    Ko, Andrew H.
    Kolli, Kanti Pallav
    Kennedy, Megan
    Laffan, Angela
    Piawah, Sorbarikor
    Pollak, Marin
    Schwartz, Gabriel
    Whitman, Julia
    Zhang, Li
    Van Loon, Katherine
    Atreya, Chloe Evelyn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345